SG11202012001YA - Ectonucleotidase inhibitors and methods of use thereof - Google Patents
Ectonucleotidase inhibitors and methods of use thereofInfo
- Publication number
- SG11202012001YA SG11202012001YA SG11202012001YA SG11202012001YA SG11202012001YA SG 11202012001Y A SG11202012001Y A SG 11202012001YA SG 11202012001Y A SG11202012001Y A SG 11202012001YA SG 11202012001Y A SG11202012001Y A SG 11202012001YA SG 11202012001Y A SG11202012001Y A SG 11202012001YA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- ectonucleotidase inhibitors
- ectonucleotidase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/048—Pyridine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/052—Imidazole radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862688225P | 2018-06-21 | 2018-06-21 | |
| US201962827505P | 2019-04-01 | 2019-04-01 | |
| PCT/US2019/038245 WO2019246403A1 (en) | 2018-06-21 | 2019-06-20 | Ectonucleotidase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202012001YA true SG11202012001YA (en) | 2021-01-28 |
Family
ID=68981317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202012001YA SG11202012001YA (en) | 2018-06-21 | 2019-06-20 | Ectonucleotidase inhibitors and methods of use thereof |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11078228B2 (en) |
| EP (1) | EP3810617A4 (en) |
| JP (1) | JP2021529172A (en) |
| KR (1) | KR20210024561A (en) |
| CN (1) | CN112888696B (en) |
| AU (1) | AU2019288495B2 (en) |
| BR (1) | BR112020025132B1 (en) |
| CA (1) | CA3104088A1 (en) |
| CL (1) | CL2020003339A1 (en) |
| CO (1) | CO2021000049A2 (en) |
| IL (1) | IL279475A (en) |
| MX (1) | MX2020013320A (en) |
| PH (1) | PH12020552214A1 (en) |
| SG (1) | SG11202012001YA (en) |
| TW (1) | TW202010750A (en) |
| WO (1) | WO2019246403A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10570167B2 (en) | 2016-12-22 | 2020-02-25 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| WO2018208980A1 (en) | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| WO2019090111A1 (en) | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CA3098493A1 (en) | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| TWI821559B (en) * | 2019-04-28 | 2023-11-11 | 大陸商上海和譽生物醫藥科技有限公司 | A CD73 inhibitor, its preparation method and application |
| AU2020294724A1 (en) * | 2019-06-20 | 2022-01-20 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| US11530236B2 (en) | 2019-10-30 | 2022-12-20 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| CN115873049B (en) * | 2023-02-13 | 2023-05-02 | 北京先通国际医药科技股份有限公司 | Preparation method and application of adenosine |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2085994A1 (en) | 1991-04-24 | 1992-10-25 | Shinji Sakata | 1-beta-d-arabinofuranosyl-(e)-5- (2-halogenovinyl) uracil derivatives |
| AU5449094A (en) | 1992-11-02 | 1994-05-24 | Affymax Technologies N.V. | Novel photoreactive protecting groups |
| US5635608A (en) | 1994-11-08 | 1997-06-03 | Molecular Probes, Inc. | α-carboxy caged compounds |
| TW528755B (en) | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| NL1005244C2 (en) | 1997-02-10 | 1998-08-18 | Inst Voor Agrotech Onderzoek | Surfactant amines and glycosides. |
| WO2004096233A2 (en) | 2003-04-25 | 2004-11-11 | Gilead Sciences, Inc. | Nucleoside phosphonate conjugates |
| EP1860113A1 (en) | 2006-05-24 | 2007-11-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ectonucleotidase inhibitors |
| ATE499940T1 (en) | 2006-07-18 | 2011-03-15 | Anadys Pharmaceuticals Inc | CARBONATE AND CARBAMAT PRODRUGS OF THIAZOLO Δ4,5-DÜ-PYRIMIDINES |
| MX2010005095A (en) | 2007-11-07 | 2010-08-03 | Schering Corp | Novel modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors. |
| EP2070938A1 (en) * | 2007-12-13 | 2009-06-17 | Heidelberg Pharma AG | Clofarabine dietherphospholipid derivatives |
| CA2684017A1 (en) | 2009-10-22 | 2011-04-22 | Universite Laval | Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification |
| US9725479B2 (en) | 2010-04-22 | 2017-08-08 | Ionis Pharmaceuticals, Inc. | 5′-end derivatives |
| US10031142B2 (en) | 2010-07-08 | 2018-07-24 | Life Technologies Corporation | In situ chemiluminescent substrates and assays |
| CN102311472B (en) | 2010-07-09 | 2014-09-03 | 神隆(昆山)生化科技有限公司 | Preparation of 2-chloro-9-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-adenine |
| US20140154675A1 (en) | 2011-05-03 | 2014-06-05 | Life Technologies Corporation | Flash and Glow 1,2-Dioxetanes |
| NZ618698A (en) * | 2011-07-15 | 2015-08-28 | Boehringer Ingelheim Int | Substituted quinazolines, the preparation thereof and the use thereof in pharmaceutical compositions |
| GB201220843D0 (en) | 2012-11-20 | 2013-01-02 | Univ College Cork Nat Univ Ie | Compound |
| EP3134411B1 (en) * | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN106463125B (en) * | 2014-04-25 | 2020-09-15 | 杜比实验室特许公司 | Audio segmentation based on spatial metadata |
| WO2017066781A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Mrna cap analogs with modified phosphate linkage |
| WO2017066782A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Hydrophobic mrna cap analogs |
| WO2017066791A1 (en) | 2015-10-16 | 2017-04-20 | Modernatx, Inc. | Sugar substituted mrna cap analogs |
| WO2017079195A1 (en) | 2015-11-02 | 2017-05-11 | Mitobridge, Inc. | Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases |
| EP3366691A1 (en) * | 2015-12-03 | 2018-08-29 | GlaxoSmithKline Intellectual Property Development Limited | Cyclic purine dinucleotides as modulators of sting |
| JP7125144B2 (en) | 2016-09-09 | 2022-08-24 | キャリセラ バイオサイエンシーズ， インコーポレイテッド | Ectonucleotidase inhibitors and methods of use thereof |
| US10570167B2 (en) | 2016-12-22 | 2020-02-25 | Calithera Biosciences, Inc. | Ectonucleotidase inhibitors and methods of use thereof |
| WO2018208727A1 (en) * | 2017-05-08 | 2018-11-15 | Eternity Bioscience Inc. | Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof |
| WO2018208980A1 (en) * | 2017-05-10 | 2018-11-15 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CN109503587B (en) * | 2017-09-14 | 2022-01-11 | 辽宁利锋科技开发有限公司 | Anti-tumor effect and application of diheterocyclic triazole nucleoside analogue |
| WO2019090111A1 (en) * | 2017-11-03 | 2019-05-09 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| CA3098493A1 (en) * | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| TW202017569A (en) * | 2018-05-31 | 2020-05-16 | 美商佩樂敦治療公司 | Compositions and methods for inhibiting cd73 |
| AU2019288495B2 (en) | 2018-06-21 | 2024-02-08 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
| AU2020294724A1 (en) | 2019-06-20 | 2022-01-20 | Antengene Therapeutics Limited | Ectonucleotidase inhibitors and methods of use thereof |
-
2019
- 2019-06-20 AU AU2019288495A patent/AU2019288495B2/en active Active
- 2019-06-20 MX MX2020013320A patent/MX2020013320A/en unknown
- 2019-06-20 CA CA3104088A patent/CA3104088A1/en active Pending
- 2019-06-20 KR KR1020217001701A patent/KR20210024561A/en unknown
- 2019-06-20 US US16/447,159 patent/US11078228B2/en active Active
- 2019-06-20 WO PCT/US2019/038245 patent/WO2019246403A1/en active Application Filing
- 2019-06-20 SG SG11202012001YA patent/SG11202012001YA/en unknown
- 2019-06-20 BR BR112020025132-1A patent/BR112020025132B1/en active IP Right Grant
- 2019-06-20 CN CN201980054369.1A patent/CN112888696B/en active Active
- 2019-06-20 EP EP19823042.7A patent/EP3810617A4/en active Pending
- 2019-06-20 JP JP2020570902A patent/JP2021529172A/en active Pending
- 2019-06-21 TW TW108121817A patent/TW202010750A/en unknown
-
2020
- 2020-12-16 IL IL279475A patent/IL279475A/en unknown
- 2020-12-18 PH PH12020552214A patent/PH12020552214A1/en unknown
- 2020-12-21 CL CL2020003339A patent/CL2020003339A1/en unknown
-
2021
- 2021-01-06 CO CONC2021/0000049A patent/CO2021000049A2/en unknown
- 2021-06-28 US US17/359,990 patent/US11858957B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112020025132B1 (en) | 2023-10-10 |
| BR112020025132A2 (en) | 2021-03-23 |
| CN112888696B (en) | 2024-04-16 |
| CL2020003339A1 (en) | 2021-06-25 |
| PH12020552214A1 (en) | 2021-08-16 |
| TW202010750A (en) | 2020-03-16 |
| EP3810617A4 (en) | 2022-06-29 |
| US11078228B2 (en) | 2021-08-03 |
| AU2019288495A1 (en) | 2021-01-28 |
| MX2020013320A (en) | 2021-02-22 |
| IL279475A (en) | 2021-01-31 |
| CO2021000049A2 (en) | 2021-04-19 |
| JP2021529172A (en) | 2021-10-28 |
| WO2019246403A1 (en) | 2019-12-26 |
| CA3104088A1 (en) | 2019-12-26 |
| US20190389899A1 (en) | 2019-12-26 |
| AU2019288495B2 (en) | 2024-02-08 |
| EP3810617A1 (en) | 2021-04-28 |
| US20230022922A1 (en) | 2023-01-26 |
| US11858957B2 (en) | 2024-01-02 |
| CN112888696A (en) | 2021-06-01 |
| KR20210024561A (en) | 2021-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3700527A4 (en) | Papd5 inhibitors and methods of use thereof | |
| HK1259232A1 (en) | Substituted inhibitors of menin-mll and methods of use | |
| EP3684361A4 (en) | Substituted inhibitors of menin-mll and methods of use | |
| IL279475A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL267291A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL287940A (en) | Fgfr inhibitors and methods of use thereof | |
| EP3510040A4 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| IL283592A (en) | Inhibitors of apol1 and methods of using same | |
| IL287751A (en) | Kcnt1 inhibitors and methods of use | |
| IL287768A (en) | Kcnt1 inhibitors and methods of use | |
| IL259801A (en) | Inhibitors of ezh2 and methods of use thereof | |
| IL287973A (en) | Acss2 inhibitors and methods of use thereof | |
| IL276711A (en) | Arginase inhibitors and methods of use thereof | |
| IL274504A (en) | Acss2 inhibitors and methods of use thereof | |
| IL278989A (en) | Masp-2 inhibitors and methods of use | |
| IL283387A (en) | Diarylhydantoin compounds and methods of use thereof | |
| IL282350A (en) | Rgmc-selective inhibitors and use thereof | |
| EP3846808A4 (en) | Papd5 inhibitors and methods of use thereof | |
| IL280924A (en) | Arginase inhibitors and methods of use thereof | |
| IL283782A (en) | Anellosomes and methods of use | |
| IL286485A (en) | Pi4-kinase inhibitors and methods of using the same | |
| IL286149A (en) | Caspase inhibitors and methods of use thereof | |
| IL276053A (en) | Therapeutic-gard and method of use thereof | |
| EP3793552C0 (en) | Abhd12 inhibitors and methods of making and using same | |
| IL266344A (en) | Inhibitors of mtor-deptor interactions and methods of use thereof |